Published in Springer Semin Immunopathol on January 01, 1985
Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol (2008) 1.54
Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods Mol Biol (2012) 1.11
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol (2006) 1.03
Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med (2012) 0.92
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol (1996) 1.55
Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol (1989) 1.55
A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology (1997) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology (2000) 1.52
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol (2001) 1.40
Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology (1994) 1.27
Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler (2009) 1.15
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology (1999) 1.12
Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology (1995) 1.10
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology (2009) 1.05
Delayed, relapsing experimental allergic encephalomyelitis in mice. J Immunol (1981) 1.03
Acute experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. Immunogenetics (1986) 0.97
Mitochondrial DNA mutations in multiple sclerosis. Mult Scler (1995) 0.96
Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol (1987) 0.95
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler (2010) 0.94
The genetics of multiple sclerosis. A review. Biomed Pharmacother (1999) 0.92
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res (1993) 0.88
The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. J Clin Psychol (1992) 0.88
Organ specific endothelial cell heterogeneity influences differential replication and cytopathogenicity of MHV-3 and MHV-4. Implications in viral tropism. Adv Exp Med Biol (1995) 0.87
Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology (2006) 0.85
Characterization of the mitochondrial DNA in patients with multiple sclerosis. J Neurol Sci (1996) 0.84
Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler (2009) 0.83
Differential modulation of MHC class I antigen expression on mouse brain endothelial cells by MHV-4 infection. J Neuroimmunol (1989) 0.83
Adoptive transfer of murine relapsing experimental allergic encephalomyelitis. Ann Neurol (1985) 0.83
Mouse hepatitis virus (MHV-4, JHM) blocks gamma-interferon-induced major histocompatibility complex class II antigen expression on murine cerebral endothelial cells. J Neuroimmunol (1991) 0.82
Syringoencephalomyelia (syringocephalus). J Neuropathol Exp Neurol (1981) 0.82
Hydrocephalus in Kartagener's syndrome. Ear Nose Throat J (1986) 0.82
Interferon-gamma-inducible endothelial cell class II major histocompatibility complex expression correlates with strain- and site-specific susceptibility to experimental allergic encephalomyelitis. J Neuroimmunol (1993) 0.82
Central nervous system and blood lymphocytes in experimental allergic encephalomyelitis. J Clin Lab Immunol (1983) 0.82
Role of myelin antigens in murine relapsing experimental allergic encephalomyelitis. J Clin Lab Immunol (1984) 0.82
Delayed, relapsing experimental allergic encephalomyelitis in mice. Role of adjuvants and pertussis vaccine. J Neurol Sci (1983) 0.81
Genetic regulation of susceptibility and severity of demyelination. Ann N Y Acad Sci (1988) 0.81
Relapsing experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. Clin Exp Immunol (1986) 0.81
Palliative care in patients with multiple sclerosis. Neurol Clin (2001) 0.80
Myokymia and impaired muscular relaxation with continuous motor unit activity. J Neurol Neurosurg Psychiatry (1979) 0.80
Effects of staphylococcal enterotoxin B on T cell receptor V beta utilization and clinical manifestations of experimental allergic encephalomyelitis. J Neuroimmunol (1993) 0.80
Immunomodulation of relapsing experimental allergic encephalomyelitis. Neurology (1984) 0.79
Neuroimmunology: modulation of the hamster immune system by photoperiod. Life Sci (1987) 0.79
Meningeal carcinomatosis complicating gynecologic malignancies: a literature review and report of a case. Obstet Gynecol Surv (1983) 0.79
Screening for Leber's hereditary optic neuropathy associated mitochondrial DNA mutations in patients with prominent optic neuritis. Mult Scler (1997) 0.79
Lower extremity motor evoked potentials in multiple sclerosis. Arch Neurol (1991) 0.79
Trigeminal neuralgia in a patient with multiple sclerosis treated with high cervical spinal cord stimulation. Case report. Appl Neurophysiol (1988) 0.78
Modulation of T cell-endothelial adhesion by astrocyte conditioned medium. Glia (1997) 0.78
Neuroendocrine regulation of immune parameters. Photoperiod control of the spleen in Syrian hamsters. Ann N Y Acad Sci (1988) 0.78
Interleukin-6 induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM). J Neuroimmunol (1993) 0.78
Impairment of central and peripheral myelin in mitochondrial diseases. Mult Scler (1997) 0.77
Regulation of MHC class I and II antigens on cerebral endothelial cells and astrocytes following MHV-4 infection. Adv Exp Med Biol (1990) 0.77
T cell receptor V beta gene utilization in myelin basic protein specific clones from CXJ1 recombinant inbred mice. J Neuroimmunol (1993) 0.77
Clomiphene as an anticonvulsant drug: A case report. Arch Neurol (1982) 0.77
Regulation of the expression of intercellular adhesion molecule-1 (ICAM-1) and the putative adhesion molecule Basigin on murine cerebral endothelial cells by MHV-4 (JHM). Adv Exp Med Biol (1993) 0.76
Combination therapy for treatment of multiple sclerosis. Ann Neurol (1998) 0.75
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2009) 0.75
A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis. J Immunol (1996) 0.75
Distribution of the blood-brain barrier in heterotopic brain transplants and its relationship to the lesions of EAE. J Neuropathol Exp Neurol (1992) 0.75
Down-regulation of gamma-interferon-induced class II expression of human glioma cells by recombinant beta-interferon. Ann N Y Acad Sci (1988) 0.75
Intracerebral beta-interferon in brain tumor therapy. Monitoring cerebral function with compressed spectral analysis. Ann N Y Acad Sci (1988) 0.75
The cellular response of JC virus T-antigen-induced brain tumor implants to a Murine intra-ocular model. J Neuroimmunol (2000) 0.75
Generation of an anti-mouse brain endothelial cell monoclonal antibody that recognizes 84-110 kDa and 36 kDa determinants that are upregulated by cytokines. Adv Exp Med Biol (1993) 0.75
The evolutionary relationship among Caucasian MS patients and controls. Mult Scler (1996) 0.75
Characteristics of the T lymphocytes involved in experimental allergic encephalomyelitis. J Neuroimmunol (1995) 0.75
Reduced S-adenosylmethionine:protein-lysine N-methyltransferase activity (protein methylase III) in shiverer mutant mouse brain. Neurochem Res (1987) 0.75
Down-regulation of interferon-gamma-induced class II expression on human glioma cells by recombinant interferon-beta: effects of dosage treatment schedule. J Neuroimmunol (1988) 0.75
Clinical characteristics of progressive relapsing multiple sclerosis. Mult Scler (2004) 0.75
Myelin basic protein-specific protein methylase I activity in shiverer mutant mouse brain. J Neurosci Res (1986) 0.75
Immunopathogenic mechanisms in experimental allergic encephalomyelitis. Curr Opin Neurol Neurosurg (1993) 0.75
Spectrum and classification of inflammatory demyelinating diseases of the central nervous system. Curr Neurol Neurosci Rep (2001) 0.75
Separation and properties of lymphocytes obtained from the central nervous system. J Clin Lab Immunol (1980) 0.75
Cytokine induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM). Adv Exp Med Biol (1993) 0.75
Heterotopic brain transplants in the study of experimental allergic encephalomyelitis. Exp Neurol (1987) 0.75
Distributional patterns of multiple sclerosis brain lesions. Magnetic resonance imaging--clinical correlation. J Neuroimaging (1994) 0.75
Immune effects of intracerebral infection with mouse hepatitis virus. Ann N Y Acad Sci (1988) 0.75
Preferential but not exclusive T cell receptor V beta chain utilization of myelin basic protein and peptide-specific T cell clones in mice. Cell Immunol (1994) 0.75